TABLE 2.
Cyclin binding sites in cyclin/cdk substrates and inhibitorsa
| Cyclin/cdk substrateor inhibitor | Sequence |
|---|---|
| p21 (N)b | KACRRLFG |
| p21 (C)b | HSKRRLIF |
| p27 | SACRNLFG |
| p57 | SACRSLFG |
| pRB | KPLKKLRF |
| p107 | SAKRRLFG |
| p130 | TTRRRLFV |
| E2F1 | PVKRRLDL |
| E2F2 | PAKRKLDL |
| E2F3 | PAKRRLEL |
| p45 (SKP2) | PTLKTLQV |
| Cdc25A | PAPRRLLF |
| PAP | SKIRILVG |
| HIRA | LSKRKLEL |
| E1 (HPV)c | KAKRRLFT |
| Consensus | ZRXL |
| SLBP | RYKRKLLI |
a
The cyclin binding sites from cdk inhibitors (p21, p27, and p57) and cdk substrates are shown and compared with the sequence in SLBP (amino acids 95 to 100).
b
The N-terminal (N) and C-terminal (C) regions of p21 are shown.
c
HPV, human papillomavirus.